Embecta (NASDAQ:EMBC) Upgraded by Wall Street Zen to “Strong-Buy” Rating

Embecta (NASDAQ:EMBC) was upgraded by investment analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Saturday.

EMBC has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Embecta in a research report on Wednesday, January 21st. BTIG Research reissued a “buy” rating and set a $25.00 target price on shares of Embecta in a research report on Friday, February 6th. One investment analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Embecta currently has an average rating of “Hold” and an average target price of $18.50.

Embecta Price Performance

NASDAQ:EMBC opened at $9.07 on Friday. Embecta has a one year low of $9.06 and a one year high of $15.55. The company has a fifty day moving average price of $11.08 and a 200 day moving average price of $12.76. The stock has a market cap of $537.13 million, a P/E ratio of 3.83 and a beta of 1.10.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings results on Thursday, February 5th. The company reported $0.71 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.04. The firm had revenue of $261.20 million during the quarter, compared to the consensus estimate of $258.07 million. Embecta had a net margin of 12.92% and a negative return on equity of 26.66%. The business’s revenue was down .3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.65 EPS. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. As a group, equities research analysts anticipate that Embecta will post 2.85 EPS for the current year.

Institutional Trading of Embecta

Hedge funds and other institutional investors have recently made changes to their positions in the business. Larson Financial Group LLC lifted its position in Embecta by 368.6% during the 3rd quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock worth $28,000 after buying an additional 1,574 shares in the last quarter. Tower Research Capital LLC TRC increased its position in Embecta by 542.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock valued at $71,000 after acquiring an additional 6,224 shares in the last quarter. Wexford Capital LP bought a new position in shares of Embecta in the third quarter worth about $94,000. Humankind Investments LLC bought a new position in shares of Embecta in the second quarter worth about $111,000. Finally, iSAM Funds UK Ltd acquired a new position in shares of Embecta during the third quarter worth approximately $115,000. 93.83% of the stock is currently owned by institutional investors and hedge funds.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.